Inhalation Sciences receives new order worth over 2 million SEK from major China inhaled pharma co.
(Stockholm October 19, 2021) Inhalation Sciences AB (ISAB) has received a new order worth 202 KEUR (2.025 MSEK) from a major inhaled pharma company in China specializing in asthma and COPD treatments for the global market. The order is for ISAB’s PreciseInhale® aerosol generating platform and its in vitro lung simulation module DissolvIt®.The comprehensive new order covers installation, tech transfer, training and service and support for ISAB’s entire PreciseInhale® platform - plus its in vitro lung simulation module DissolvIt®. DissolvIt® is widely recognized as being a leading solution in